CRISPR Therapeutics AG reported earnings of -$ 1.15 per CRSP share on Nov 2, 2026, beating analysts' expectations by
| Report Date | Nov 2, 2026 |
|---|---|
| Forecasted EPS | -$ 1.04 |
| Earnings Per Share (Surprise) | -$ 1.15 (-$ 0.11) |
| Last Year's EPS | -$ 1.56 |
| EPS YoY Change |
Out of the last 48 earnings reporting periods, CRISPR Therapeutics AG beat analysts’ expectations 19 times and fell short of expectations 23 time(s). CRISPR Therapeutics AG reported earnings per share of -$ 1.15 in the last report falling to reach an estimated EPS of -$ 1.04 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Nov 2, 2026 | -$ 1.04 | -$ 1.15 | -$ 1.17 | |
| Aug 3, 2026 | -$ 1.19 | -$ 0.94 | -$ 2.40 | |
| May 4, 2026 | -$ 1.19 | -$ 1.28 | -$ 1.29 | |
| Feb 12, 2026 | -$ 1.15 | -$ 1.37 | -$ 1.58 | |
| Nov 10, 2025 | -$ 1.26 | -$ 1.17 | -$ 0.44 | |
| Aug 5, 2025 | -$ 1.47 | -$ 2.40 | -$ 1.01 | |
| Aug 4, 2025 | -$ 1.47 | -$ 1.29 | -$ 1.49 | |
| May 6, 2025 | -$ 1.27 | -$ 1.58 | -$ 1.43 | |
| Feb 11, 2025 | -$ 1.15 | -$ 0.44 | $ 1.10 | |
| Nov 5, 2024 | -$ 1.33 | -$ 1.01 | -$ 1.41 | |
| Aug 5, 2024 | -$ 1.37 | -$ 1.49 | -$ 0.98 | |
| May 8, 2024 | -$ 1.63 | -$ 1.43 | -$ 0.67 | |
| Feb 21, 2024 | -$ 0.07 | $ 1.10 | -$ 1.41 | |
| Nov 6, 2023 | -$ 1.98 | -$ 1.41 | -$ 2.24 | |
| Aug 7, 2023 | -$ 2.18 | -$ 0.98 | -$ 2.40 | |
| May 8, 2023 | -$ 1.67 | -$ 0.67 | -$ 2.32 | |
| Feb 21, 2023 | -$ 2.32 | -$ 1.41 | -$ 1.84 | |
| Nov 1, 2022 | -$ 2.30 | -$ 2.24 | -$ 1.67 | |
| Aug 8, 2022 | -$ 2.23 | -$ 2.40 | $ 9.44 | |
| May 9, 2022 | -$ 1.91 | -$ 2.32 | -$ 1.51 |
CRISPR Therapeutics AG’s stock was trading at $ 51.42 on Nov 1, 2026 a day before the last earnings report was released.Following the release of the earnings report, CRSP’s price decreased to $ 49.99 on Nov 3, 2026, recording a
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Nov 2, 2026 | -$ 1.15 | $ 51.42 | $ 49.99 | |
| Aug 3, 2026 | -$ 0.94 | $ 47.99 | $ 53.07 | |
| May 4, 2026 | -$ 1.28 | $ 51.63 | $ 52.38 | |
| Feb 12, 2026 | -$ 1.37 | $ 48.32 | $ 53.07 | |
| Nov 10, 2025 | -$ 1.17 | $ 55.12 | $ 55.21 | |
| Aug 5, 2025 | -$ 2.40 | $ 59.59 | $ 56.34 | |
| Aug 4, 2025 | -$ 1.29 | $ 56.09 | $ 55.59 | |
| May 6, 2025 | -$ 1.58 | $ 37.62 | $ 34.25 | |
| Feb 11, 2025 | -$ 0.44 | $ 39.41 | $ 43.30 | |
| Nov 5, 2024 | -$ 1.01 | $ 50.59 | $ 50.72 | |
| Aug 5, 2024 | -$ 1.49 | $ 51.11 | $ 49.33 | |
| May 8, 2024 | -$ 1.43 | $ 55.53 | $ 53.55 | |
| Feb 21, 2024 | $ 1.10 | $ 78.73 | $ 86.19 | |
| Nov 6, 2023 | -$ 1.41 | $ 50.99 | $ 58.58 | |
| Aug 7, 2023 | -$ 0.98 | $ 50.96 | $ 53.05 | |
| May 8, 2023 | -$ 0.67 | $ 55.79 | $ 63.42 | |
| Feb 21, 2023 | -$ 1.41 | $ 50.89 | $ 50.38 | |
| Nov 1, 2022 | -$ 2.24 | $ 52.34 | $ 54.68 | |
| Aug 8, 2022 | -$ 2.40 | $ 81.40 | $ 75.13 | |
| May 9, 2022 | -$ 2.32 | $ 48.01 | $ 47.31 |
CRISPR Therapeutics AG released its most recent earnings reports in November 2026, August 2026, May 2026, February 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
CRISPR Therapeutics AG missed analysts’ expectations during the last earnings period by
